BRAF

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Brain, RAF, Survival, NSCLC, Disease, Colorectal cancer, Cetuximab, Patient, CNS, The central science, Lung cancer, BRAF, AACR, Therapy, CRC, Poster, CCCC, Mutation, Vaccine

CFT1946 is an orally bioavailable BiDAC™ degrader that selectively degrades the BRAF V600X mutant protein and prevents RAF dimer-mediated resistance.

Key Points: 
  • CFT1946 is an orally bioavailable BiDAC™ degrader that selectively degrades the BRAF V600X mutant protein and prevents RAF dimer-mediated resistance.
  • Further, in a significant number of patients with BRAF V600X melanoma and NSCLC, the disease metastasizes to the brain.
  • Promising activity of CFT1946 as a single agent in a broad range of BRAF V600X preclinical models, including models of BRAFi resistance.
  • Details of the poster are as follows:
    Title: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
Friday, April 5, 2024
CD4, CD8, AMP, Development, Antigen, Immunotherapy, Colorectal cancer, Memory, Patient, Lung, GM-CSF, Biomarker, DNA, Epitope, Cancer, Granzyme B, BRAF, Lymph, IL2, Circulating tumor DNA, Phenotype, Neoplasm, Research and development, Immunization, Therapy, Vaccination, CRC, V600E, Immune system, Melanoma, Granzyme, Phase 1, Amphetamine, Nature Medicine, Annual general meeting, Vaccine

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, April 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Administration, EGFR, Mutation, Index, Colorectal cancer, Cetuximab, Central nervous system, Novartis, Webcast, Patient, GBM, CNS, Neoplasm, Acquisition, G&A, Insurance, BRAF, NRAS, MEK, CRC, Melanoma, ASCO, ID, MTD, Research and development, Probability, Data, FDA, Outsourcing, FTD, Pharmaceutical industry

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2023.

Key Points: 
  • In addition, a strategic pipeline prioritization sharpened Erasca’s focus on existing programs that we believe have the highest probability of success for patients.
  • Research and Development (R&D) Expenses: R&D expenses were $24.8 million for the quarter ended December 31, 2023, compared to $29.4 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $9.1 million for the quarter ended December 31, 2023, compared to $8.7 million for the quarter ended December 31, 2022.
  • Erasca will hold a conference call and webcast on Thursday, March 28, 2024 at 8:30 am ET.

FORE Biotherapeutics to Present Nonclinical Data at the 2024 AACR Annual Meeting Supporting Superior Potency for Plixorafenib Compared with BRAF or Pan-Raf Inhibitors, When Combined with MEK Inhibition

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, BRAF, Meki, Binimetinib, BRAF V600, Cell, MEK, Pharmaceutical industry

The data show nonclinical synergistic activity of plixorafenib when combined with MEK inhibition across all BRAF alterations tested.

Key Points: 
  • The data show nonclinical synergistic activity of plixorafenib when combined with MEK inhibition across all BRAF alterations tested.
  • In cells with BRAF V600 or non-V600 mutations or BRAF fusions, the combination of plixorafenib and binimetinib is most potent of the BRAF and pan-RAF inhibitors tested.
  • To date, plixorafenib has demonstrated encouraging efficacy and safety data from the phase 1/2a study; these nonclinical data help build the foundation for potential future development of plixorafenib in combination with a MEK inhibitor.
  • Poster Title: The paradox-breaker BRAF inhibitor plixorafenib (PLX8394; FORE8394) synergizes with MEK inhibitors (MEKi) in BRAF V600 and non-V600 alterations, with higher potency compared to early generation BRAFi and pan-RAFi

EmeritusDX Announces Launch of FDA Approved Therascreen BRAF and KRAS Tests, Expanding Molecular Testing Capabilities

Retrieved on: 
Monday, April 8, 2024
Biopsy, Mutation, Colorectal cancer, Encorafenib, Cetuximab, Patient, Cancer, BRAF, Panitumumab, CRC, FDA, Physician, Health, Pharmaceutical industry

LAKE FOREST, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- EmeritusDX, a leading cancer diagnostics and information company, is excited to announce the launch of the FDA-approved therascreen® BRAF and KRAS tests. These innovative products represent a significant advancement in the company's molecular testing menu and aligns perfectly with its strategy of enhancing patient care.

Key Points: 
  • LAKE FOREST, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- EmeritusDX, a leading cancer diagnostics and information company, is excited to announce the launch of the FDA-approved therascreen® BRAF and KRAS tests.
  • These innovative products represent a significant advancement in the company's molecular testing menu and aligns perfectly with its strategy of enhancing patient care.
  • "The introduction of the therascreen® BRAF and KRAS portfolio is a testament to this commitment.
  • According to EmeritusDX's Chief Scientist, Dr. Vincent Funari, "The therascreen® BRAF and KRAS tests are a game-changer in personalized medicine for CRC patients.

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
Diamond, Research, Administration, EGFR, Mutation, RAF, Development, HGG, Patient, GBM, Neoplasm, Cancer, Lung cancer, BRAF, AACR, Treatment, Investment, NRAS, Clinical trial, Therapy, Poster, FDA, Food, Pharmaceutical industry

The presentation included clinical data from 27 patients with advanced/metastatic NSCLC who received once daily doses ranging from 25mg to 400mg.

Key Points: 
  • The presentation included clinical data from 27 patients with advanced/metastatic NSCLC who received once daily doses ranging from 25mg to 400mg.
  • The trial is currently in dose escalation with an update anticipated in the fourth quarter of 2024.
  • (NCT05786924)
    Cash Position: Black Diamond ended 2023 with approximately $131.4 million in cash, cash equivalents, and investments compared to $122.8 million as of December 31, 2022.
  • Net Loss: Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Strategic management, Diagnosis, Initiation, Research and development, Conference, Immunotherapy, Part, FAK, New Drug Application, Patient, Cancer, RAMP, Accelerated approval (FDA), NDA, Table, SGO, BRAF, Society, IND, Abstract, Bank statement, AACR, Pancreatic cancer, Investment, Verastem Oncology, MEK, Therapy, Safety, GAAP, Gynecologic Oncology (journal), Food, FDA, Annual general meeting, Pharmaceutical industry

Verastem Oncology ended the fourth quarter of 2023 with cash, cash equivalents and investments of $137.1 million.

Key Points: 
  • Verastem Oncology ended the fourth quarter of 2023 with cash, cash equivalents and investments of $137.1 million.
  • Research & development expenses for the 2023 Quarter were $22.5 million, compared to $10.7 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $8.6 million, compared to $6.1 million for the 2022 Quarter.
  • These non-GAAP financial measures exclude certain amounts or expenses from the corresponding financial measures determined in accordance with GAAP.

Nested Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NST-628, a Novel Pan-RAF/MEK Molecular Glue

Retrieved on: 
Thursday, March 28, 2024
Therapeutic index, RAF, Biotechnology, PD, Part, Patient, BRAF, IND, Therapy, MEK, Safety, Pharmacokinetics, FDA, Food, Pharmaceutical industry

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for NST-628 for the treatment of patients with advanced solid tumors harboring genetic alterations in the RAS-MAPK pathway. NST-628 is a mechanistically novel, fully brain penetrant non-degrading pan-RAF/MEK molecular glue that targets RAF and MEK nodes in the RAS-MAPK pathway.

Key Points: 
  • NST-628 is a mechanistically novel, fully brain penetrant non-degrading pan-RAF/MEK molecular glue that targets RAF and MEK nodes in the RAS-MAPK pathway.
  • "We believe that NST-628 has the potential to provide a differentiated clinical profile, including a superior therapeutic index and prevention of pathway reactivation, for patients with advanced solid tumors harboring RAS-MAPK pathway alterations.
  • The study includes two parts: dose escalation (Part A) followed by dose expansion (Part B).
  • The primary objectives for Part A are delineating NST-628's safety profile and establishing the recommended dose for Part B.

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
BRAF, Cancer, Vaccination, Epitope, Therapy, Lymph, Vaccine

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced three upcoming poster presentations at the American Association for Cancer Research (“AACR”) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.

Key Points: 
  • BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced three upcoming poster presentations at the American Association for Cancer Research (“AACR”) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.
  • The presentations will highlight data on Elicio’s therapeutic cancer vaccine candidates, ELI-002, ELI-007 and ELI-008, built using Elicio’s Amphiphile (“AMP”) technology, which harnesses the power of the lymph nodes to generate and activate T cells to target solid tumors.
  • Presentation Title: Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer
    Presentation Title: AMP-peptide vaccination against multiple p53 mutant epitopes promotes lymph node delivery to generate potent, functional T cell immunity
    Presentation Title: AMP-peptide vaccination against mutant BRAF epitopes promotes lymph node delivery to generate potent, functional T cell immunity